XML 74 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Reporting
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Segment Reporting
Segment Reporting
The Company evaluates performance based on the operating profit (loss) of the respective business segments. The segment results may not represent actual results that would be expected if they were independent, stand-alone businesses. Segment information is as follows:
Balance Sheet Data:
 
 
 
 
 
 
As of December 31, 2013
 
Ligand
 
CyDex
 
Total
Total Assets
$
38,408

 
$
66,305

 
$
104,713

 
 
 
 
 
 
 
As of December 31, 2012
 
Ligand
 
CyDex
 
Total
Total Assets
$
28,731

 
$
75,529

 
$
104,260

 
For the year ended December 31, 2013
 
Ligand
 
CyDex
 
Total
Net revenues from external customers
$
21,436

 
$
27,537

 
$
48,973

Operating income
253

 
14,690

 
14,943

Depreciation and amortization expense
233

 
2,430

 
2,663

Write-off of in-process research and development
—

 
480

 
480

Income tax (expense) benefit from continuing operations
(419
)
 
45

 
(374
)
Interest expense, net
2,077

 
—

 
2,077

Gain on sale of Avinza Product Line before income taxes
2,588

 
—

 
2,588

 
 
 
 
 
 
 
For the year ended December 31, 2012
 
Ligand
 
CyDex
 
Total
Net revenues from external customers
$
19,582

 
$
11,806

 
$
31,388

Operating (loss) income
(919
)
 
1,112

 
193

Depreciation and amortization expense
222

 
2,505

 
2,727

Interest expense, net
2,924

 
—

 
2,924

Income tax benefit from continuing operations
1,096

 
95

 
1,191

Gain on sale of Avinza
3,656

 
—

 
3,656

Income tax expense from discontinuing operations
(1,509
)
 
—

 
(1,509
)